NCT06409429Not yet recruitingPhase 2
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital1 site in 1 country146 target enrollmentStarted: May 1, 2024Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 146
- Locations
- 1
- Primary Endpoint
- relapse-free survival (RFS)
Study Overview
Brief Summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with GX for postoperative adjuvant treatment of pancreatic cancer.
Detailed Description
This clinical study is designed as a prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy and safety of Nimotuzumab combined with GX (gemcitabine plus capecitabine) compared with GX only for resected pancreatic cancer. About 146 patients will be enrolled in this study and randomly divided into experimental group (nimotuzumab plus GX) and control group (placebo plus GX) at a ratio of 1:1. The main endpoint is relapse-free survival (RFS). Additional end points included distant metastasis-free survival (DMFS), overall survival (OS), tumor-related markers and safety.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Able and willing to provide a written informed consent.
- •Age 18-75 years old, gender unlimited;
- •Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;
- •Postoperative pathology suggested R0/R1 resection;
- •Adequate organ and bone marrow function, defined as follows: absolute neutrophil count (ANC)≥1.5×10^9/L; platelets≥100×10^9/L; hemoglobin≥9.0 g/dL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance > 60 mL/min;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •Postoperative survival is expected to be ≥3 months;
- •Fertile subjects are willing to take contraceptive measures during the study period.
Exclusion Criteria
- •Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma;
- •Accompanied by other serious diseases, including but not limited to: active infections; unmanageable diabetes mellitus and uncontrolled hypertension (SBP>160mmHg or DBP>100mmHg); compensatory heart failure (NYHA grade III and IV), unstable angina or poorly controlled arrhythmias within 3 months prior to randomization; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency and Severe lung disease; Central Nervous System Disease or mental illness;
- •History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
- •bleeding or clotting disorder;
- •5.Postoperative complications such as bleeding, pancreatic fistula, gastric obstruction, abdominal infection, and biliary fistula, which made the patient unable to receive adjuvant therapy within 12 weeks after surgery;
- •Known allergy to prescription or any component of the prescription used in this study;
- •Factors that significantly affect oral drug absorption, such as dysphagia, chronic diarrhea, gastrointestinal obstruction, etc;
- •Known HIV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);
- •9.Other reasons that are not suitable to participate in this study according to the researcher's judgment
Arms & Interventions
Experimental group (Nimotuzumab+ GX)
Experimental
Intervention: Nimotuzumab (Drug)
Experimental group (Nimotuzumab+ GX)
Experimental
Intervention: GX (Drug)
Control group (Placebo+ GX)
Placebo Comparator
Intervention: GX (Drug)
Control group (Placebo+ GX)
Placebo Comparator
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
relapse-free survival (RFS)
Time Frame: Up to 24 months
The time from the date of surgery to the disease recurrence or death, whichever is earlier.
Secondary Outcomes
- distant metastasis-free survival (DMFS)(Up to 24 months)
- overall survival (OS)(Up to 24 months)
- tumor-related markers(Up to 24 months)
- adverse events(Up to 30 days after last administration.)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary BypassCardiac SurgeryCardiopulmonary BypassNCT02037555Grifols Therapeutics LLC425
Recruiting
Not Applicable
A Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseAcute Exacerbation of Chronic Obstructive Pulmonary DiseaseNCT06134063Peking University People's Hospital375
Active, not recruiting
Phase 2
A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic StrokeAcute Ischemic StrokeNCT05188417GrandPharma (China) Co., Ltd.266
Not yet recruiting
Phase 3
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal CancerRefractory Metastatic Colorectal CancerNCT06343116Biotech Pharmaceutical Co., Ltd.420
Recruiting
Phase 3
Efficacy and Safety of Pirfenidone Capsules in the Treatment of PneumoconiosisPneumoconiosisNCT05288179Beijing Continent Pharmaceutical Co, Ltd.272